Solaris Reports 475m of 1.03% CuEq from Surface in New Drilling as Further Productivity Gains Drive Record 10km Drilled in August

QUITO, Ecuador, Sept. 19, 2024 (GLOBE NEWSWIRE) — Solaris Resources Inc. (TSX: SLS; NYSE: SLSR) (“Solaris” or the “Company”) is pleased to report assay results from its ongoing 60,000m 2024 drilling program that aims to target open extensions of mineralization while upgrading mineral resources and converting waste at its Warintza Project (“Warintza” or “the Project”) […]

Plug Power Launches an Equipment Lease Financing Platform – Plug is Targeting >$150 million from a Combination of Debt Leverage & Customer Financing Solutions

SLINGERLANDS, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, has announced the establishment of an equipment leasing platform and is targeting over $150 million in the near to mid-term. This platform is intended to enable Plug to access capital

CW Petroleum Corp (OTCQB: CWPE) Yahoo Finance Stock Quote Data from OTC Markets Not Functioning Properly for CWPE

Katy, Texas, Sept. 19, 2024 (GLOBE NEWSWIRE) — CW Petroleum Corp (OTCQB: CWPE) (the “Company”), a leading provider of Specialty Renewable and Hydrocarbon Motor Fuels, today announces to its investors and future investors it has had numerous discussions with OTC Markets regarding Yahoo Finance and Apple Stocks App powered by Yahoo Finance for providing inaccurate

FactSet Reports Results for Fourth Quarter 2024

Q4 GAAP revenues of $562.2 million, up 4.9% from Q4 2023. Organic Q4 ASV plus professional services of $2,272.8 million, up 4.8% year over year. Q4 GAAP operating margin of 22.7%, up approximately 110 bps year over year, and adjusted operating margin of 35.8%, up 240 bps from the prior year. Q4 GAAP diluted EPS

PyroGenesis Congratulates its Client EarthGrid on its Joint Venture with EnerTech to Deploy US$18B in Plasma-Powered Tunnel Boring Projects

MONTREAL, Sept. 19, 2024 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, is pleased to congratulate its client EarthGrid, which announced yesterday

Achilles Therapeutics Announces Strategic Update

-Achilles to discontinue development of TIL-based cNeT therapy- -Cash position of $95.1 million as of June 30, 2024- -BofA Securities engaged to provide strategic financial advice- LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL) today announced the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and

OTC Markets Group Welcomes Slam Corp. to OTCQX

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Slam Corp. (OTCQX: SLAMF), a special purpose acquisition company led by World Series Champion Alex Rodriguez, has qualified to trade on the OTCQX(R) Best Market. Slam Corp. previously

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s nomlabofusp Phase 1 studies and Phase 2 dose exploration study, some of which has been previously disclosed, will be presented at

Guardian Capital Announces Fund Name Change

TORONTO, Sept. 19, 2024 (GLOBE NEWSWIRE) — Guardian Capital LP (the “Manager“), the manager of Guardian i3 US Quality Growth ETF (the “Fund“), today announced that it has changed the name of the Fund effective immediately to Guardian i3 US Quality Growth Fund (the “Name Change“). There are no changes to the investment objective, strategies

Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced the appointment of Matthias Will, M.D., as Chief Development Officer. Dr. Will is joining Autolus’ executive team and will lead the company’s development organization effective September 30, 2024. “Matthias has a proven

Scroll to Top